TaiCon Bio Announces Board Approval of Q1 2026 Consolidated Financial Report

TaiCon Bio's board of directors approved its consolidated financial report for the first quarter of 2026 on May 12, 2026. The company reported revenue of 308,435K but incurred a net loss of 142,242K.
Financial ReportNQ 0/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 12, 2026 at 09:00
  • 🔍 Collected: May 13, 2026 at 08:00 (23h 0m after Published)
  • 🤖 AI Analyzed: May 13, 2026 at 10:22 (2h 22m after Collected)
1. Date of Board of Directors Meeting or Resolution: 115/05/12
2. Date Approved by Audit Committee: 115/05/12
3. Reporting Period for Financial Report or Self-Assessed Annual Financial Information (XXX/XX/XX~XXX/XX/XX): 115/01/01~115/03/31
4. Cumulative Operating Revenue from January 1 to this Period (K): 308,435
5. Cumulative Gross Profit (or Loss) from January 1 to this Period (K): 64,956
6. Cumulative Operating Profit (or Loss) from January 1 to this Period (K): (207,240)
7. Cumulative Profit (or Loss) Before Tax from January 1 to this Period (K): (141,836)
8. Cumulative Net Profit (or Loss) for this Period from January 1 to this Period (K): (142,242)
9. Cumulative Net Profit (or Loss) Attributable to Parent Company Owners from January 1 to this Period (K): (142,242)
10. Cumulative Basic Earnings Per Share (Loss) (Yuan): (0.47)
11. Total Assets at End of Period (K): 10,619,357
12. Total Liabilities at End of Period (K): 2,413,133
13. Equity Attributable to Parent Company Owners at End of Period (K): 8,206,224
14. Other Disclosures: None